Dosage guide · 80 mg blend

KLOW Blend Dosage Protocol

Fixed-ratio four-peptide research blend

The reference protocol uses a total-blend amount of 2 mg once daily for weeks 1–2, then 4 mg, 6 mg and back to 4 mg through week 12. With 3 mL of bacteriostatic water, the 80 mg vial is 26.67 mg/mL, so the 2 mg starting amount is 7.5 units on a U-100 syringe. These total amounts contain the fixed component shares shown below.

How oftenOnce daily

Starting dose2 mg

Start = units7.5 units

Mix3 mL BAC water

Reviewed 25 Oct 2026 · Education only, not medical advice

KLOW Blend 80 mg blend vial

View on Peak Peptides Also at Pure Performance

Exact Peak Peptides Australia product photo

Dosage chart How to mix Supplies Calculator About KLOW Blend References

01 · DOSAGE CHART

KLOW Blend dosage chart

12-week daily approach · 80 mg blend + 3 mL BAC water

BAC water added

Concentration26.67 mg/mL totalUnequal blend — see split below

1 unit (U-100)266.7 mcg total= 0.01 mL

How oftenOnce dailySubcutaneous injection

3 mL is the reference protocol mix and is also shown on Peak's KLOW page, giving 26.67 mg/mL total blend.

KLOW Blend dosage chart for a 80 mg blend vial mixed with 3 mL of bacteriostatic water
Week	Total blend dose	Syringe units
Weeks 1–2Start	2 mg1.25 mg GHK-Cu + 250 mcg BPC-157 + 250 mcg TB-500 + 250 mcg KPV	7.5 units0.075 mL
Weeks 3–4	4 mg2.5 mg GHK-Cu + 500 mcg BPC-157 + 500 mcg TB-500 + 500 mcg KPV	15 units0.15 mL
Weeks 5–8	6 mg3.75 mg GHK-Cu + 750 mcg BPC-157 + 750 mcg TB-500 + 750 mcg KPV	22.5 units0.225 mL
Weeks 9–12Maintenance	4 mg2.5 mg GHK-Cu + 500 mcg BPC-157 + 500 mcg TB-500 + 500 mcg KPV	15 units0.15 mL

Once daily · subcutaneous injection

Amounts are total blend per administration: 2 mg contains 1.25 mg GHK-Cu and 250 mcg of each other component; the fixed ratio remains the same at every step.

The attribution source shows this 12-week example and does not establish an optimal time of day.

Community-reported total-blend amounts — KLOW has no approved or clinically established human dose. Education only, not medical advice. Dose amounts adapted from KLOW 80 mg vial dosage protocol (PeptideDosages.com); units are recalculated for the vial and mix selected above.

02 · HOW TO MIX

Mixing a 80 mg blend vial with 3 mL of BAC water

Using a 1 mL (100-unit) insulin syringe, 3 full draws of bacteriostatic water gives 26.67 mg/mL in total.

1
Add the water slowly
Wipe both rubber stoppers with an alcohol swab and let them dry. Draw 3 mL of bacteriostatic water and let it run slowly down the inside of the vial wall — not straight onto the powder.
2
Swirl gently
Swirl or roll the vial gently until the powder has dissolved. Give it a few minutes to settle if needed.
3
Don't shake it
Shaking can damage the peptide and cause foaming. Gentle swirling only.
4
Check it's fully clear
Only use it once it is fully clear with no particles. Label the vial with the date and 26.67 mg/mL, then store it in the fridge at 2–8 °C.

Full illustrated reconstitution guide

03 · SUPPLIES NEEDED

What you'll need

Counts follow the dosage chart above at the highest amount in each step, using a 80 mg blend vial mixed with 3 mL.

Length of protocol

2KLOW Blend 80 mg blend vials84 mg needed in total

301 mL insulin syringesU-100, 27–31G · one per draw + one per vial mixed

1BAC water 10 mL bottle6 mL used for mixing

60Alcohol swabsSkin + stopper, every time

Plus an approved sharps container. Syringes and swabs are sold by Australian pharmacies — Peak Peptides and Pure Performance supply the bacteriostatic water.

KLOW Blend 80 mg blend vialPeak Peptides Australia KLOW Blend 80 mg blend vialPure Performance Australia

Peak Peptides Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPeak Peptides Australia

Pure Performance Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPure Performance Australia

04 · CALCULATOR

Check a different amount

Enter the total blend amount; the split between peptides follows the blend ratio shown in the chart.

Concentration Calculator

Labelled Vial Amount (mg)

Verified Final Liquid Volume3 mL

Amount to Evaluate (not a recommendation)

Concentration

26.67 mg/mL

(26667 mcg/mL)

Calculated Liquid Volume

0.075 mL

Equivalent U-100 volume scale position

7.5markings (not biological IU)

Illustration of a U-100 volume scale, not preparation or injection guidance

05 · PROTOCOL DETAILS

About KLOW Blend

Protocol overview

Starting amount: 2 mg total blend once daily
How it increases: 4 mg in weeks 3–4, 6 mg in weeks 5–8, then 4 mg in weeks 9–12
Frequency: Once daily
When to take it: No optimal time is established in the attribution source
Example length: 12 weeks
Common mix: 3 mL bacteriostatic water → 26.67 mg/mL total blend

Storage

Before mixing: Store the lyophilised powder at −20 °C in dry, dark conditions.
After mixing: Keep refrigerated at 2–8 °C and protected from light.
Never: Avoid repeated freeze–thaw cycles or use if the solution is cloudy or has visible particles.

How it works

KLOW is a fixed-ratio mixture of GHK-Cu, BPC-157, TB-500 and KPV. Research on individual ingredients does not establish the effects, compatibility, route or administration schedule of this four-component mixture.

GHK-Cu is a copper-binding tripeptide studied largely in skin and laboratory research. KPV reduced inflammatory signalling in cultured cells and experimental colitis in mice, while BPC-157 and thymosin beta-4 research includes mostly preclinical tissue-repair work. These mechanisms are not proof of clinical benefit from injectable KLOW.

Illustrated mechanism explainer

What the research shows

No controlled human study of the four-component KLOW blend was identified for this guide; the attribution page presents a community educational calculation rather than a clinical regimen.
A 2025 systematic review of BPC-157 included 36 studies, of which 35 were preclinical and one was clinical; in the small retrospective human report, 7 of 12 people with chronic knee pain reported relief for more than 6 months after an intra-articular injection. This does not validate KLOW or its subcutaneous schedule.
A trial of full-length synthetic thymosin beta-4, not TB-500 fragment, enrolled four cohorts of 10 healthy volunteers. Intravenous 42–1,260 mg doses, including daily administration for 14 days, had no dose-limiting toxicity or serious adverse events in that study.
In a KPV experiment, 100 μM KPV in drinking water for 8 days reduced inflammatory measures in two mouse colitis models; the DSS comparison used 5 mice per group. This is not human evidence or injectable KLOW evidence.
The TGA identifies products containing BPC-157, GHK-Cu and TB-500 as examples of unapproved peptide products that have not been evaluated by the TGA for safety, quality or effectiveness.

Reported side effects

Human safety information for the KLOW combination is absent, so its adverse-effect profile, interactions and long-term risks are unknown.
The TGA reports serious adverse effects associated with unapproved peptide products, including liver damage, severe allergic reactions requiring hospitalisation, inflammation and other complications. These reports do not establish that KLOW caused a specific event.
FDA states that compounded BPC-157 may pose immunogenicity and peptide-impurity risks, while it identifies limited human safety data for injectable GHK-Cu and no human exposure data for KPV or thymosin beta-4 fragment products.
A BPC-157 intravenous pilot involved only 2 adults receiving 10 mg on day 1 and 20 mg on day 2; it reported no side effects or measured blood-marker changes, but it cannot establish safety of KLOW or subcutaneous use.

Important notes

KLOW is not an approved medicine in Australia. The TGA lists BPC-157, GHK-Cu and TB-500 among unapproved peptide products that have not been assessed for safety, quality or effectiveness.
Prohibited in sport at all times: WADA lists BPC-157 under S0 and lists thymosin beta-4 and its derivatives, including TB-500, under S2.
The fixed-ratio label does not verify sterility, identity, stability, compatibility or clinical effectiveness of a supplied vial. The TGA warns that unapproved injectable peptide products can involve contamination, dosing uncertainty and unknown substances.
The chart reproduces a community educational calculation, not a clinically validated combined human regimen.
Never use a mixed vial that is cloudy or has particles in it.

Injection basics

Use a new sterile 1 mL (100-unit) U-100 insulin syringe, 27–31G, every time — never reuse or share.
Wipe the vial stopper and the skin with an alcohol swab and let both dry first.
Inject under the skin (subcutaneously) of the abdomen, thigh or upper arm, and rotate sites.
Put used syringes straight into an approved sharps container — the NDSS lists Australian disposal options.

Guidance: World Health Organization · National Diabetes Services Scheme (NDSS)

06 · QUICK ANSWERS

KLOW Blend questions

How many units is the 2 mg KLOW Blend starting amount?

With 3 mL in an 80 mg vial, the total concentration is 26.67 mg/mL. A 2 mg total-blend amount is 7.5 units, or 0.075 mL, on a U-100 syringe. It contains 1.25 mg GHK-Cu plus 250 mcg each of BPC-157, TB-500 and KPV.

How much bacteriostatic water for an 80 mg KLOW vial?

The attribution protocol and Peak's KLOW page show 3 mL. That makes 26.67 mg/mL total blend, where 1 U-100 unit is 266.67 mcg total blend. Pure's product page instead gives a 2 mL research preparation, which would be 40 mg/mL.

How many units are the 4 mg and 6 mg KLOW Blend amounts?

With the default 3 mL mix, 4 mg total blend is 15 units (0.15 mL) and 6 mg total blend is 22.5 units (0.225 mL) on a U-100 syringe.

How long does an 80 mg KLOW Blend vial last?

At 2 mg total blend once daily, an 80 mg vial provides 40 days. At 4 mg once daily it provides 20 days, and at 6 mg once daily it provides about 13.33 days. These are concentration calculations, not a validated use schedule.

07 · SOURCES